New Report Reveals Alarming Decline in Women’s Cancer Testing Worldwide
21.1.2025 14:00:00 CET | Business Wire | Press release
Women’s cancer testing has declined globally, according to the latest Hologic Global Women’s Health Index, one of the largest collections of data on women’s health and well-being.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250121461870/en/
Hologic, Inc. (Nasdaq: HOLX), a leading women’s health innovator, partners with Gallup to create the Index. Now in its fourth year, the Index raises new concerns about declining trends in women’s health. For the first time in the history of the Index, women’s cancer testing declined: Only 10% of women surveyed worldwide said they were tested for any type of cancer in the past year, down two percentage points from the first two years of the Index.
This year’s Index will be released today during an event convened by Goals House, a community focused on driving progress toward the United Nations (UN) Sustainable Development Goals (SDGs) alongside the World Economic Forum in Davos, Switzerland. The event will feature a panel including Dr. Natalia Kanem, Executive Director of the United Nations Population Fund (UNFPA), Dr. Sania Nishtar, CEO, Gavi, The Vaccine Alliance and Elissa Miolene, Global Development Reporter, Devex.
“Today’s data reveal a worsening trend in women’s health,” said Stephen P. MacMillan, Chairman, President and CEO of Hologic. “The shocking decline in cancer testing is a wake-up call. Business as usual is not working. Innovative strategies and collaborative efforts are needed to make sustained improvements in women’s health and well-being around the world.”
Key findings from this year’s Index:
- Cancer Screening Among Women Declined: Only 10% of women said they underwent any type of cancer testing in the past year, reflecting a decrease of two percentage points from the first two years of the survey.
- Women Are Struggling More to Meet Basic Needs: A staggering 38% of women reported being unable to afford food at some point in the past year, marking the highest level of food insecurity in nearly two decades. And 32% of women said they could not afford adequate shelter.
- More Women Are Worried and Sad: More women reported feeling worried (42%) and sad (30%) compared to Year 1 of the Index. And over one third (35%) said they felt unsafe in their communities.
- Ongoing Physical Pain and Health Issues:34% of women reported experiencing significant pain the previous day, while 26% indicated that health problems impacted their ability to engage in everyday activities.
- HIV Testing Rates for Women Are Alarmingly Low: The Index assessed women’s HIV testing for the first time and found concerning disparities: Less than0.5% of women were tested in certain countries, primarily those in the Middle East and North Africa, and no country scored above 41%. Globally, the percentage is much lower. Just 6% of women — regardless of whether they visited a healthcare professional or were tested for STIs — said they were tested for HIV in the past year.
- Signs of Hope — Some Countries Are Making Progress:28 countries saw meaningful increases in their Index scores since the first year of the Index, including Kazakhstan, Kenya, Poland and Venezuela.
The Index assigns a women’s health score to each country or territory based on survey responses on five dimensions of health. Overall, the world scored 53 out of 100 on the Index in Year 4, reflecting no significant change since the Index started.
Taiwan led the world for the fourth consecutive year, scoring 68 out of a possible 100. Other top scores went to Kuwait (67), Austria (66) and Switzerland (65). The lowest scores went to Afghanistan (30), the Democratic Republic of Congo (34) and Chad (35). The United States scored 60 – on par with New Zealand (60) and Lithuania (60) – and fell seven places from its ranking in the third year of the Index to 37 out of 142 countries and territories.
The Index fills a critical gap in knowledge about the health, safety and well-being of women worldwide. Based on interviews with more than 146,000 women and men in 142 countries and territories, it represents the voices of 97% of the world’s women and girls aged 15 and older.
To see the full Index and related resources, visit WomensHealthIndex.com.
About Hologic, Inc.
Hologic, Inc. is a global leader in women’s health, dedicated to developing innovative medical technologies that effectively detect, diagnose and treat health conditions and raise the standard of care around the world. For more information on Hologic, visit www.hologic.com and connect with us on LinkedIn, Facebook, X, Instagram and YouTube.
Hologic and The Science of Sure are trademarks and/or registered trademarks of Hologic, Inc. and/or its subsidiaries in the United States and/or other countries.
About Gallup
Gallup delivers analytics and advice to help leaders and organizations solve their most pressing problems. Combining more than 80 years of experience with its global reach, Gallup knows more about the attitudes and behaviors of employees, customers, students and citizens than any other organization in the world.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250121461870/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Reply S.p.A: The Board of Directors Approves theHalf-year Financial Reportas of 30 June 202630.7.2026 13:52:00 CEST | Press release
All economic and financial indicators grew:Consolidated turnover of €1,311.9 million (1,221.3 in H1 2025);EBITDA of €233.2 million (223.7 in H1 2025);EBIT a of €189.7 million (188.4 in H1 2025);Pre-tax profit of €194.1 million (179.4 in H1 2025). Today, the Board of Directors of Reply S.p.A. [EXM, STAR: REY] approved the results as at 30 June 2026. Since the start of the year, the Group has recorded a consolidated turnover of €1,311.9 million which is an increase of 7.4% compared to the same period in 2025. All indicators are positive for the period. In the first half of 2026 consolidated EBITDA of €233.2 million compared to the €223.7 million recorded in 2025 and corresponds to 17.8% of turnover. EBIT, from January to June, was €189.7 million (€188.4 million in 2025), corresponding to 14.5% of turnover. Pre-tax profit, from January to June 2026, was €194.1 million (€179.4 million in 2025), corresponding to 14.8% of turnover. As regards the second quarter of 2026, the Group's performan
De' Longhi Group: a Quarter of Robust Revenue Growth of 8.4% and Solid Margin Expansion Drives an Upward Guidance Revision30.7.2026 13:47:00 CEST | Press release
Substantial expansion in Professional and acceleration in Household drive growth and margins, enabling further investments in marketing and product innovation as part of the Group's continuous strategic evolution The Board of Directors of De' Longhi S.p.A. approved the consolidated results1 for the first half of 2026: In the first half the Group achieved: revenues for € 1,676.3 million, up by 5.8% with respect to last year (+8.0% at constant currency); an adjusted2 Ebitda of € 283.7 million, equal to 16.9% on revenues (vs. 15.2% in H1-25); a net income pertaining to the Group equal to € 141.4 million (+21.2% with respect to last year); a positive net financial position equal to € 686.6 million. CEO Fabio de' Longhi commented: “The solid results for the first half of 2026 provide the ideal backdrop to celebrate our first twenty-five years as a listed company. This milestone marks a transformative journey in which, thanks to the commitment and passion of our people, we have consistently
White Paper Examines Early Clinical Development of B-Cell Depletion Therapies in Autoimmune Disease30.7.2026 13:01:00 CEST | Press release
Novotech, a leading global full-service clinical research organization (CRO) and scientific advisory company, has released a new white paper, B-Cell Depletion in Autoimmune Disease: Considerations for Early Clinical Development, providing practical guidance on the scientific, clinical, and operational factors shaping the development of emerging B-cell depletion therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260730139661/en/ B-cell depletion has become an important area of research in autoimmune disease as developers investigate whether deeper and more sustained depletion may support longer periods of remission and potentially influence immune system recovery. Emerging approaches, including in vivo CAR-T therapies and T-cell engagers, are expanding the range of development strategies available beyond established B-cell-targeting treatments. The white paper looks at the early development decisions sponsors face as t
Industrial Info Resources Launches IIR Envoy™ MCP, Bringing Human-Verified Industrial Intelligence Directly Into AI Through Model Context Protocol30.7.2026 13:00:00 CEST | Press release
Model Context Protocol (MCP) connectivity brings 40 years of human-verified energy and industrial intelligence directly into the AI tools professionals already use. Industrial Info Resources (IIR), a leading provider of energy and industrial market intelligence built on primary research and human verification, today announced the launch of IIR Envoy MCP; this new Model Context Protocol connection plugs IIR's authoritative industrial database directly into the AI platforms professionals already use. As an example, with IIR Envoy MCP, an analyst can ask, "What refinery capacity is offline in Europe since this morning's weather event?" or "Which power plants near Houston have upcoming outages?" and receive an instant, source-cited answer drawn from IIR's live data. As AI becomes increasingly embedded in decision-making tools, the quality of AI-generated insights depends entirely on the quality of the underlying data. IIR Envoy MCP was built on that principle. "The information age was abou
120 Million AI Pay Transactions in a Single Week: AI Shopping Agents Move From Theory to Checkout30.7.2026 12:45:00 CEST | Press release
Agentic commerce is beginning to move from forecast to real-world use in some markets. In China, AI agents are already completing purchases at meaningful scale, and analysts now put the global opportunity at $3–5 trillion by 2030. The debate is shifting as early examples show AI shopping agents completing transactions in some markets. According to NielsenIQ (NYSE: NIQ), a leading consumer intelligence company, its global report The Commerce Revolution: Where East Meets West points to agentic commerce moving from experiment toward everyday infrastructure. According to Ant Group, Alipay AI Pay processed more than 120 million transactions during the week of February 5–11, 2026, while Adobe Analytics reported that traffic from generative AI sources to US retail websites increased by 1,200% between July 2024 and February 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260730837106/en/ Agentic commerce is beginning to move fr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom